Skip to content
Disclosery

Versant Venture Management, LLC

Follow

13F filer, CIK 1560009, San Francisco, CA

Versant Venture Management, LLC reported $212,452,986 across 9 holdings for the quarter ended 2025-09-30, in a 13F-HR filed 2025-11-10.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001193125-25-274459

Period
2025-09-30
Reported value
$212M
Holdings
9
Top 10 weight
100%
New
1
Sold out
0

Largest buys vs the previous quarter

SecurityShares changeApprox. value
LENZnew+2,656,888$124M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
CRSPreduced-349,727-$22.7M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2025

Share positions as resolved from 13F-HR 0001193125-25-274459, largest first. % of portfolio is the value over $212,452,986, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
LENZLENZ THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 2,656,888 shares 2,656,888$124M58.25%newTimeline
GLUEMONTE ROSA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 5,652,922 shares; 2025Q1: 5,652,922 shares; 2025Q2: 5,652,922 shares; 2025Q3: 5,652,922 shares 5,652,922$41.9M19.72%0Timeline
JBIOJADE BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 1,525,820 shares; 2025Q3: 1,525,820 shares 1,525,820$13.2M6.2%0Timeline
CRSPCRISPR THERAPEUTICS AGQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 498,558 shares; 2024Q4: 498,558 shares; 2025Q1: 498,558 shares; 2025Q2: 498,558 shares; 2025Q3: 148,831 shares 148,831$9.65M4.54%-349,727Timeline
SKYESKYE BIOSCIENCE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,007,704 shares; 2024Q4: 2,007,704 shares; 2025Q1: 2,007,704 shares; 2025Q2: 2,007,704 shares; 2025Q3: 2,007,704 shares 2,007,704$7.89M3.71%0Timeline
CTNMCONTINEUM THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 918,163 shares; 2024Q4: 918,163 shares; 2025Q1: 918,163 shares; 2025Q2: 542,628 shares; 2025Q3: 542,628 shares 542,628$6.38M3%0Timeline
REPARE THERAPEUTICS INCREPARE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,646,657 shares; 2024Q4: 2,646,657 shares; 2025Q1: 2,646,657 shares; 2025Q2: 2,646,657 shares; 2025Q3: 2,646,657 shares 2,646,657$4.66M2.19%0
Tempest Therapeutics, Inc.Tempest Therapeutics, Inc.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 3,507,055 shares; 2025Q1: not reported; 2025Q2: 269,772 shares; 2025Q3: 269,772 shares 269,772$2.77M1.31%0
Adverum Biotechnologies, In…Adverum Biotechnologies, Inc.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 506,821 shares; 2024Q4: 506,821 shares; 2025Q1: 506,821 shares; 2025Q2: 506,821 shares; 2025Q3: 506,821 shares 506,821$2.3M1.08%0

How Q3 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001193125-25-274459 base2025-11-10acceptance time not in the bulk data set